PetVivo announces release of study results involving feline tolerance of Spryng

PetVivo Holdings announced that the Company has released the results of a clinical study conducted by Inotiv, an independent clinical research organization, which examined the safety of intra-articular injections of collagen-elastin hydrogel microparticulates into the joints of cats. “We are pleased to have the release of the final results of this Spryng tolerance study as this data demonstrates the safety of our veterinary medical device, Spryng, when injected into the joints of cats,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We continue to strive to provide data demonstrating that Spryng is a viable tool to use in the management of joint related afflictions found in companion animals, such as cats.”